BioCryst Pharmaceuticals Inc (BCRX)
5.34
+0.24
(+4.71%)
USD |
NASDAQ |
May 09, 16:00
5.63
+0.29
(+5.43%)
Pre-Market: 20:00
BioCryst Pharmaceuticals Research and Development Expense (Quarterly): 46.49M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 46.49M |
| December 31, 2023 | 70.05M |
| September 30, 2023 | 46.88M |
| June 30, 2023 | 51.25M |
| March 31, 2023 | 48.39M |
| December 31, 2022 | 73.21M |
| September 30, 2022 | 52.74M |
| June 30, 2022 | 61.99M |
| March 31, 2022 | 65.36M |
| December 31, 2021 | 63.53M |
| September 30, 2021 | 49.97M |
| June 30, 2021 | 52.87M |
| March 31, 2021 | 42.44M |
| December 31, 2020 | 35.35M |
| September 30, 2020 | 30.24M |
| June 30, 2020 | 27.50M |
| March 31, 2020 | 29.87M |
| December 31, 2019 | 26.77M |
| September 30, 2019 | 25.12M |
| June 30, 2019 | 27.68M |
| March 31, 2019 | 27.49M |
| December 31, 2018 | 23.43M |
| September 30, 2018 | 22.01M |
| June 30, 2018 | 21.01M |
| March 31, 2018 | 18.44M |
| Date | Value |
|---|---|
| December 31, 2017 | 16.92M |
| September 30, 2017 | 17.51M |
| June 30, 2017 | 15.76M |
| March 31, 2017 | 16.77M |
| December 31, 2016 | 12.16M |
| September 30, 2016 | 14.10M |
| June 30, 2016 | 14.17M |
| March 31, 2016 | 20.58M |
| December 31, 2015 | 19.05M |
| September 30, 2015 | 20.07M |
| June 30, 2015 | 16.52M |
| March 31, 2015 | 17.12M |
| December 31, 2014 | 18.51M |
| September 30, 2014 | 13.04M |
| June 30, 2014 | 11.07M |
| March 31, 2014 | 9.183M |
| December 31, 2013 | 15.47M |
| September 30, 2013 | 7.735M |
| June 30, 2013 | 11.53M |
| March 31, 2013 | 7.215M |
| December 31, 2012 | 8.786M |
| September 30, 2012 | 12.07M |
| June 30, 2012 | 12.78M |
| March 31, 2012 | 15.52M |
| December 31, 2011 | 14.21M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
25.12M
Minimum
Sep 2019
73.21M
Maximum
Dec 2022
46.39M
Average
47.63M
Median
Research and Development Expense (Quarterly) Benchmarks
| Integra Lifesciences Holdings Corp | 26.96M |
| Krystal Biotech Inc | 10.96M |
| AIM ImmunoTech Inc | 3.20M |
| Protalix BioTherapeutics Inc | 3.102M |
| Armata Pharmaceuticals Inc | 7.928M |